Edison encouraged by prescription data for Orexo's Zubsolv

10 August 2015

Edison Research on Monday said it is encouraged by recent prescription data for Swedish drug developer Orexo’s (STO: ORX) dropped Zubsolv (buprenorphine/naloxone CIII sublingual tablet) after the insurer CVS Caremark dropped it from its list of prescription drug insurance.

The broker in a research report noted the company’s announcement that its exclusive managed Medicaid agreement will offset the losses from changes in Zubsolv’s status at CVS Caremark.

The broker said at second-quarter 2015 Orexo it is encouraged by the new multi-year agreement adding that it has not made any changes to its forecasts and 6 billion Swedish kronor ($682.6 million). Edison said it believes the share price is overly discounting Zubsolv’s potential, implying peak gross sales of $430 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK